Wiegand G, May TW, Lehmann I, et al. - High efficacy of long-term treatment with everolimus (EVO) for therapy-resistant epilepsy in tuberous sclerosis complex (TSC) was evident, along with its safety and good tolerability. EVO can treat therapy-resistant epilepsy in TSC but it can take a long time for seizure relief to manifest.

• This study involved 15 patients with TSC and therapy-resistant epilepsy who were given EVO after a 3-month baseline, and were followed up for up to 10 years (minimum 0.6 years, median 5.8 years).

• A significant decrease in seizure frequency or an increase in seizure-free days was observed in 12 patients (80%): six (40%) were seizure-free and four patients (26.7%) were seizure free for > 7 years, of which three needed no additional antiseizure medication.

• At least one adverse effect, mostly (92.5%) mild or moderate, occurred in all patients.